Brain tumor therapy by combined vaccination and antisense oligonucleotide delivery with nanoparticles

Journal of Neuroimmunology

Volumn 195, Issue 1-2, 2008, Pages 21-27

  Schneider, Thomas ^a   Becker, Andreas ^a   Ringe, Kerstin ^a   Reinhold, Annegret ^b   Firsching, Raimund ^a   Sabel, Bernhard A ^a  

^a Department of Neurosurgery ^*  (Germany)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Active specific immunization; Fischer rats; Glioma; Nanoparticles; TGF

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; BETA GALACTOSIDASE; FLUORESCEIN ISOTHIOCYANATE; NANOPARTICLE; POLYBUTYL CYANOACRYLATE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD25+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; FISCHER 344 RAT; GENE TRANSFER; GLIOBLASTOMA; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHUMAN; PRIORITY JOURNAL; RAT; REPORTER GENE; TUMOR CELL; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; BLOOD CELL COUNT; BRAIN NEOPLASMS; CANCER VACCINES; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETIC VECTORS; GLIOBLASTOMA; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; NANOPARTICLES; OLIGONUCLEOTIDES, ANTISENSE; RATS; RATS, INBRED F344; SURVIVAL ANALYSIS; TRANSFORMING GROWTH FACTOR BETA; TUMOR CELLS, CULTURED; VACCINATION;

EID: 41949094382     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2007.12.005     Document Type: Article

References (40)

1. Alyautdin R.N., Tezikov E.B., Ramge P., Kharkevich D.A., Begley D.J., and Kreuter J. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. J. Microencapsul. 15 (1998) 67-74
2. Badie B., and Black K.L. Immunotherapy of primary malignant brain tumors. Crit. Rev. Neurosurg. 4 (1994) 89-94
3. Brooks W., Netsky M.G., Normansell D.E., and Horwitz D.A. Depressed cell mediated immunity in patients with primary intracranial tumors. J. Exp. Med. 136 (1972) 1631-1647
4. Darley R., Morris A., Passas J., and Bateman W. Interactions between interferon γ and retinoic acid with transforming growth factor β in the induction of immune recognition molecules. Cancer Immunol. Immunother. 37 (1993) 112-118
5. Fine H.A., Dear K.B.G., Loeffler J.S., Black P.M., and Canellos G.P. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71 (1993) 2585-2597
6. Fontana A., Bodmer S., Frei K., Malipiero U., and Siepl C. Expression of TGF-β 2 in human glioblastoma: a role in resistance to immune rejection?. Ciba Foundation Symposium. Clinical applications of TGF-b vol. 157 (1991), Wiley, Chichester 232-238
7. Fontana A., Constam D.B., Frei K., Malipiero U., and Pfister H.W. Modulation of the immune response by transforming growth factor beta. Int. Arch. Allergy. Immunol. 99 (1992) 1-7
8. Geary R.S., Yu R.Z., Watanabe T., Henry S.P., Hardee G.E., Chappell A., Matson J., Sasmor H., Cummins L., and Levin A.A. Pharmacokinetics of a tumor necrosis factor-alpha phosphorothioate 2′-O-(2-methoxyethyl) modified antisense oligonucleotide: comparison across species. Drug Metab. Dispos. 31 (2003) 1419-1428
9. Gelperina S.E., Khalansky A.S., Skidan I.N., Smirnova Z.S., Bobruskin A.I., Severin S.E., Turowski B., Zanella F.E., and Kreuter J. Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicol.Lett. 126 (2002) 131-141
10. Gulyaev A.E., Gelperina S.E., Skidan I.N., Antropov A.S., Kivman G.Y., and Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm.Res. 16 (1999) 1564-1569
11. Holladay F.P., Heitz T., Chen Y.L., Chiga M., and Wood G.W. Successful treatment of a malignant rat glioma with cytotoxic T lymphocytes. Neurosurgery 31 (1992) 528-533
12. Jachimczak P., Bogdahn U., Schneider J., Behl C., Meixensberger J., Apfel R., Dorries R., et al. The effect of transforming growtth factro-beta 2-specific phosphorothioate-anti-sense oligodeoxynucleotides in reversing cellular immunosuppression in malignant glioma. J. Neurosurg. 78 (1993) 944
13. Jachimczak P., Hessdörder B., Fabel-Schulte K., Wismeth C., Brysch W., Schlingensiepen K.-H., Bauer A., Blesch A., and Bogdahn U. Transforming growth factor-β-mediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides. Int. J. Cancer 65 (1996) 332-337
14. Jacobs S.T., Wilson D.J., Kornblith P.L., and Grimm E.A. In vitro killing of human glioblastoma by interleukin-2-activated autologous lymphocytes. J. Neurosurg. 64 (1986) 114-117
15. Kaul G., and Amiji M. Tumor-targeted gene delivery using poly(ethylene glycol)-modified gelatin nanoparticles: in vitro and in vivo studies. Pharm.Res. 22 (2005) 951-961
16. Kehrl J.H., Roberts A.B., Wakefield L.M., Jakowlew S.B., Sporn M.B., and Fauci A.S. Transforming growth factor beta is an important immunomodulatory protein for human B-lymphocytes. J. Immunol. 137 (1986) 3855-3860
17. Kehrl J.H., Wakefield L.M., Roberts A.B., Jakowlew S.B., Alvarez-Mon M., Derynck R., Sporn M.B., and Fauci A.S. Production of transforming growth factor β by human T lymphocytes and its potential role in the regulation of T cell growth. J. Exp. Med. 163 (1986) 1037-1050
18. Kornblith P.L., and Walker M. Chemotherapy for malignant gliomas. J. Neurosurg. 68 (1988) 1-17
19. Kreuter J., Alyautdin R.N., Kharkevich D.A., and Ivanov A.A. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res. 674 (1995) 171-174
20. Kreuter J., Petrov V.E., Kharkevich D.A., and Alyautdin R.N. Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood-brain barrier using surfactant-coated nanoparticles. J. Contr. Rel. 49 (1997) 81-87
21. Kreuter J., Ramge P., Petrov V., Hamm S., Gelperina S.E., Engelhardt B., Alyautdin R., Von Briesen H., and Begley D.J. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm. Res. 20 (2003) 409-416
22. Kreuter J., Shamenkov D., Petrov V., Ramge P., Cychutek K., Koch-Brandt C., and Alyautdin R. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J. Drug Target 10 (2002) 317-325
23. Kuppner M.C., Hamou M.F., Sawamura Y., Bodmer S., and de T.N. Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor beta 2. J. Neurosurg. 71 (1989) 211-217
24. Lillehei K.O., Mitchell D.H., Johnson S.D., McCleary E.L., and Kruse C.A. Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy. Neurosurgery 28 (1991) 16-23
25. Mahaley Jr. M.S., Bigner D.D., Dudka L.F., Wilds P.R., Williams D.H., Bouldin T.W., Whitaker J.N., and Bynum J.M. Immunobiology of primary intracranial tumors. Part 7: active immunization of patients with anaplastic human glioma cells: a pilot study. J. Neurosurg. 59 (1983) 201-207
26. Maxwell M., Galanopoulos T., Neville-Golden J., and Antoniades H.N. Effect of the expression of transforming growth factor-β2 in primary human glioblastomas on immunosuppression and loss of immune surveillance. J. Neurosurg. 76 (1992) 799-804
27. Minami Y., Kono T., Miyazaki T., and Taniguchi T. The IL-2 receptor complex: its structure, function, and target genes. Annu. Rev. Immunol. 11 (1993) 245-268
28. Nakada Y., Fattal E., Foulquier M., and Couvreur P. Pharmacokinetics and biodistribution of oligonucleotide adsorbed onto poly(isobutylcyanoacrylate) nanoparticles after intravenous administration in mice. Pharm. Res. 13 (1996) 38-43
29. Naujoks G., Schmitz A., Schramm J., Wiestler O.D., and Schirrmacher V. Peripheral immunization against malignant rat glioma can induce effective anti-tumor immunity in the brain. Int. J. Oncol. 6 (1995) 759-765
30. Oldfield E.H., Ram Z., Culver K.W., Blaese R.M., De Vromm H.L., and Anderson W.F. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum. Gene Ther. 4 (1993) 39-69
31. Ramge P., Unger R.E., Oltrogge J.B., Zenker D., Begley D., Kreuter J., and Von Briesen H. Polysorbate-80 coating enhances uptake of polybutylcyanoacrylate (PBCA)-nanoparticles by human and bovine primary brain capillary endothelial cells. Eur. J. Neurosci. 12 (2000) 1931-1940
32. Reinhold D., Bank U., Buhling F., Junker U., Kekow J., Schleicher E., and Ansorge S. A detailed protocol for the measurement of TGF-beta1 in human blood samples. J. Immunol. Methods 209 (1997) 203-206
33. Roszman T., Elliott L., and Brooks W. Modulation of T-cell function by gliomas. Immunol. Today 12 (1991) 370-374
34. Schirrmacher V., Ahlert T., Pröbstle T., Steiner H.-H., Herold-Mende C., Gerhards R., and Hagmüller E. Immunization with virus-modified tumor cells. Semin. Oncol. 25 (1998) 677-696
35. Schlingensiepen R., and Schlingensiepen K.-H. Antisense oligodeoxynucleotides-highly specific tools for basic research and pharmacotherapy. In: Schlingensiepen R., Brysch W., and Schlingensiepen K.-H. (Eds). Antisense- from technology to therapy (1997), Blackwell Wissenschaft, Berlin, Wien 3-28
36. Schneider Th., Gerhards R., Kirches E., and Firsching R. Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme. J. Neuro-Oncol. 53 (2001) 39-46
37. Schröder U., and Sabel B.A. Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of i.v. dalargin injections. Brain Res. 710 (1996) 121-124
38. Schroeder U., Sommerfeld P., and Sabel B.A. Efficacy of oral dalargin-loaded nanoparticle delivery across the blood-brain barrier. Peptides 19 (1998) 777-780
39. Schroeder U., Sommerfeld P., Ulrich S., and Sabel B.A. Nanoparticle technology for delivery of drugs across the blood-brain barrier. J. Pharm. Sci. 87 (1998) 1305-1307
40. Steiniger S.C., Kreuter J., Khalansky A.S., Skidan I.N., Bobruskin A.I., Smirnova Z.S., Severin S.E., Uhl R., Kock M., Geiger K.D., and Gelperina S.E. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int. J. Cancer 109 (2004) 759-767